BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 12769339)

  • 21. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
    Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
    Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience.
    Silvani A; Salmaggi A; Eoli M; Lamperti E; Broggi G; Marras CE; Fariselli L; Milanesi I; Fiumani A; Gaviani P; Erbetta A; Giovagnoli AR; Pollo B; Botturi A; Boiardi A
    J Neurooncol; 2007 May; 82(3):273-9. PubMed ID: 17111190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
    Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
    Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
    Maza S; Kiewe P; Munz DL; Korfel A; Hamm B; Jahnke K; Thiel E
    Neuro Oncol; 2009 Aug; 11(4):423-9. PubMed ID: 19060176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
    Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
    Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
    Vanazzi A; Grana C; Crosta C; Pruneri G; Rizzo S; Radice D; Pinto A; Calabrese L; Paganelli G; Martinelli G
    Hematol Oncol; 2014 Mar; 32(1):10-5. PubMed ID: 23696416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late relapse in primary central nervous system lymphoma: clonal persistence.
    Nayak L; Hedvat C; Rosenblum MK; Abrey LE; DeAngelis LM
    Neuro Oncol; 2011 May; 13(5):525-9. PubMed ID: 21372070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
    Doolittle ND; Jahnke K; Belanger R; Ryan DA; Nance RW; Lacy CA; Tyson RM; Haluska M; Hedrick NA; Varallyay C; Neuwelt EA
    Leuk Lymphoma; 2007 Sep; 48(9):1712-20. PubMed ID: 17786706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
    McAllister LD; Doolittle ND; Guastadisegni PE; Kraemer DF; Lacy CA; Crossen JR; Neuwelt EA
    Neurosurgery; 2000 Jan; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
    Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
    Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
    Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
    Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.